The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: A randomized phase II trial: An update.
Rasha Mohamed Haggag
No relevant relationships to disclose
Kamel Farag
No relevant relationships to disclose
Fouad Abu-Taleb
No relevant relationships to disclose
Sameh Shamaa
No relevant relationships to disclose
Abdel-Rahman Zekri
No relevant relationships to disclose
Tarek ELBolkainy
No relevant relationships to disclose
Hussein Mustafa Khaled
No relevant relationships to disclose